MetaCap

Coya Therapeutics (COYA) vs MAIA Biotechnology (MAIA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

MAIA Biotechnology (MAIA) has outperformed Coya Therapeutics (COYA) over the past year, gaining 21.7% versus a loss of 50.7%. Coya Therapeutics is the larger company by market cap ($69.2 million vs $68.5 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

COYA-50.67%MAIA+21.71%
+237%+85%-67%
Nov 21, 20251 yearNov 20, 2026
COYA-37.74%MAIA-68.38%
+123%+20%-84%
Dec 26, 20225 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

COYA versus MAIA key metrics
MetricCOYAMAIA
Share price$2.95$1.11
Market cap$69.20M$68.54M
1-day change-1.01%-2.63%
YTD return-49.14%-27.45%
1-year return-50.67%+21.71%
EPS (TTM)$-1.39$-0.47
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$7.95M—
Revenue growth (YoY)+123.57%—
Net income (latest FY)$-21.23M$-22.40M
Operating margin-283.87%—
Net margin-267.14%—
52-week high$6.62$3.19
52-week low$2.72$0.895
Distance from 52-week high-55.44%-65.20%
Analyst consensusstrong_buynone
Avg. price target upside+415.59%+981.08%
Average volume149.18K524.29K
Shares outstanding23.46M61.75M
Employees813
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • MAIA has outperformed COYA by 72.4 percentage points over the past year.

About Coya Therapeutics

COYA stock →

Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary therapies to enhance the function of regulatory T cells (Tregs). Its candidate product pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.

Health Care · Biotechnology: Pharmaceutical Preparations · 8 employees

About MAIA Biotechnology

MAIA stock →

MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer. Its lead product Ateganosine, a telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC).

Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees

COYA vs MAIA FAQ

Which is bigger, Coya Therapeutics or MAIA Biotechnology?

Coya Therapeutics (COYA) is larger, with a market capitalization of $69.20M compared with $68.54M for MAIA Biotechnology (MAIA).

Which stock has performed better over the past year, COYA or MAIA?

MAIA returned +21.71% over the past 12 months, compared with -50.67% for COYA (price return, excluding dividends). Past performance does not predict future results.

Are Coya Therapeutics and MAIA Biotechnology in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons